Donor-Derived CAR-T Therapy Improves the Survival of Relapsed B-ALL after Allogeneic Transplantation Compared with Donor Lymphocyte Infusion

Researchers conducted a single-center, retrospective comparative study that consisted of 12 patients who were treated with donor lymphocyte infusion and 12 patients treated with donor-derived CD19 CAR-T cells with 3 overlaps.